奎硫平与利培酮治疗女性精神分裂症92例的对照研究  

Comparative study on female schizphrenics by Quetiapine and Risperidone

作　　者：赵业华[1] 胡俊艳[1] 吴迎春[1] 

机构地区：[1]辽宁省精神卫生中心,辽宁开原112300

出　　处：《中国民康医学》2012年第5期521-523,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:探讨奎硫平治疗女性精神分裂症的疗效及安全性。方法:92例女性精神分裂症患者随机分为奎硫平组45例和利培酮组47例,疗程8周。采用阳性与阴性症状量表(PANSS)评价疗效,临床总体印象量表(CGI-SI)评价病情严重程度,治疗中出现的症状量表(TESS)评价不良反应。结果:奎硫平组显效率为66.7%,有效率86.7%,利培酮组分别为68.1%和85.1%,两组差异无显著性;但两组体质量较治疗前均明显增加。结论:奎硫平治疗女性精神分裂症疗效与利培酮相当,均能引起体质量增加。Objective：To evaluate the efficacy of Quetiapine to treat female schizophrenics. Methods ：92 female schizophrenic patients were randomly divided into Quetiapine group （n = 45 ） and Risperidone group （n = 47 ）. The therapeutic period was 8 weeks. The positive and negative symptoms scale （PANSS） and clinical global impressions -severity of illness rating scale （CGI -SI） were used to rate the efficacy; the treatment emergent symptom scale （TESS） was used to measure side effects. Results： There were no sig- nificant differences between Quetiapine group and Rispefidone group in markedly response rate （66.7% vs 68.1% ） and improved rate （86.7% vs 85.1% ）. The body weights in both groups were significantly increased after treatment. Conclusions： Quetiapine has similar efficacy as Risperidone in treatment of female schizophrenic patients, with body weights increase.

关 键 词：精神分裂症 奎硫平 利培酮 女性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]